Tevogen Bio's T-Cell Therapy Approach Stands Out, Analyst Sees Strong Potential

On Tuesday, D Boral Capital initiated coverage on Tevogen Bio Holdings Inc. TVGN, a clinical-stage immunotherapy company.The company’s lead pipeline product, TVGN-489, is a SARS-CoV-2-specific therapy.Tevogen’s pipeline includes preclinical programs targeting Epstein-Barr virus-associated lymphomas (TVGN -930), human papillomavirus-related cervical cancer (TVGN -920), multiple sclerosis (TVGN -601), and HPV-related mouth and throat cancer (TVGN-960).Also Read: Amazon To Launch AI Reasoning Model In June, Re ...